nor-beta-lapachone and quinone

nor-beta-lapachone has been researched along with quinone* in 2 studies

Other Studies

2 other study(ies) available for nor-beta-lapachone and quinone

ArticleYear
Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
    European journal of medicinal chemistry, 2017, Mar-31, Volume: 129

    In this work, we mainly focused on discovering compounds with good selectivity for NQO1 over CPR. The NQO1-mediated two-electron reduction of compounds would kill cancer cells selectively, while CPR-mediated one-electron reduction would induce potential hepatotoxicity. Several novel quinone-directed antitumor agents were discovered as specific NQO1 substrates through structure-activity relationship studies. Among them, compound 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-dione (12b) emerged as the most specific substrate of the two-electron oxidoreductase NQO1 and could hardly be reduced by CPR. It afforded the highest selectivity between NQO1/CPR (selectivity ratio = 6.37), much higher than the control β-lapachone (selectivity ratio = 1.36), indicated 12b may possess superior safety profile. The electrochemical studies provided a reasonable explanation to the good selectivity toward NQO1. Molecular docking studies supported that 12b was capable of forming additional C-H … π interactions with Trp105 and Phe178 residues compared to the control β-lap. In addition, compound 12b was shown to kill cancer cells efficiently both in vitro and in vivo model. This work gave us a promising and novel scaffold for further investigation.

    Topics: Antineoplastic Agents; Benzoquinones; Binding Sites; Cell Death; Drug Discovery; Humans; Molecular Docking Simulation; NAD(P)H Dehydrogenase (Quinone); NADPH-Ferrihemoprotein Reductase; Patient Safety; Reactive Oxygen Species; Structure-Activity Relationship

2017
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Thirty two compounds were synthesized in moderate to high yields and showed activity against cancer cells HL-60 (leukemia), MDA-MB435 (melanoma), HCT-8 (colon) and SF295 (central nervous system), with IC(50) below 2 μM for some compounds. The β-lapachone-based 1,2,3-triazoles showed the best cytoxicity profile and emerge as promising anticancer prototypes. Insights about the reactive oxygen species (ROS) mechanism of anticancer action for some compounds were obtained by addition of 1-bromoheptane that deplete reduced glutathione (GSH) content and by using N-acetylcysteine that protects cells against apoptotic cellular death, as well by analysis of thiobarbituric acid reactive substances (TBARS) formation, and oxidative DNA damage after treatment detected by the comet assay with the bacterial enzymes formamidopyrimidine DNA-glycosylase (FPG) and endonuclease III (ENDOIII).

    Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Survival; DNA Breaks; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50

2011